You are here

CMS Report: Nexium, Advair Led Medicare Drug Spending in 2013

New data offer first detailed look at Part D costs and services

Four brand-name drugs prescribed to older or disabled Americans covered by Medicare’s drug benefit accounted for almost one-tenth of the $103 billion in prescriptions filled under the plan in 2013, the Centers for Medicare & Medicaid Services (CMS) has reported.

The CMS said Nexium (esomeprazole, AstraZeneca) for acid reflux topped the list, with prescriptions totaling $2.5 billion, followed by $2.3 billion for the asthma drug Advair (fluticasone propionate/salmeterol, GlaxoSmithKline). Third place went to the cholesterol-lowering drug Crestor (rosuvastatin, AstraZeneca), with $2.2 billion worth of prescriptions, while the anti-psychotic agent Abilify (aripiprazole, Otsuka Corp.) came in fourth, with $2.1 billion.

The data cover prescriptions filled under the Medicare Part D prescription drug program. Approximately 68% of all Medicare beneficiaries (36 million people) are enrolled in the Part D program, according to the CMS. For the first time, the new dataset provides information on more than 1 million health care providers who collectively prescribed $103 billion in prescription drugs under the Part D program.

Although the top 10 most-prescribed drugs were all branded medications, the top 10 by number of claims were all generics.

The most-prescribed Medicare drug was lisinopril, a cardiovascular medication that treats hypertension, with 36.9 million prescriptions (at a total drug cost of $307 million). It was followed by the cholesterol-lowering drug simvastatin, with 36.7 million prescriptions (at a total cost of $434 million), and the thyroid drug levothyroxine sodium, with 35.2 million prescriptions (at a total cost of $396 million).

The five prescriber specialties with the highest total Part D drug costs were: internal medicine (at a total cost of $27 billion), family practice (at a total cost of $22 billion), nurse practitioner (at a total cost of $7 billion), neurology, and psychiatry (each at a total cost of $5 billion).

Psychiatry had the highest generic dispensing rate (81.9%), and both internal medicine and neurology had the lowest (each 76.1%).

According to the CMS, the new spending data were released “to help drive transformation of the health care delivery system.”

Sources: CMS; April 30, 2015; and Reuters; April 30, 2015.

Recent Headlines

Safety concerns include liver injury and interactions with other drugs
No tobacco product is safe, says the lung heath group
Discovery seen as possibly leading to new anti-TB drugs
Study points to permanent hair dye and straighteners
How malaria parasites evade first-line drugs
A new way to fight staph infections
Score could help prevent misuse among cancer patients